Triple Negative Breast Cancer News and Research

RSS

Discovering a new role for a protein that could cause breast cancer to spread to the lungs

In this interview, News-Medical speaks to Dr. Cristina Branco from Breast Cancer Now about the spread of breast cancer cells to the lungs.

12 Nov 2020

A promising vaccine for treating poorly immunogenic tumors

Patients with cancer have multiple treatment options available to them today, but each has its drawbacks. Chemotherapy kills rapidly dividing cancer cells, but it also damages healthy cells in the body and often does not effectively prevent tumor metastasis or disease recurrence.

11 Nov 2020

Biomarkers that are predictive of clinical benefit in Trop-2-expressing triple-negative breast cancer

Oncotarget recently published "Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer" which reported that the authors investigated whether Trop-2-expression and homologous recombination repair of SN-38-mediated double-strand DNA breaks play a role in the sensitivity of triple-negative breast cancer to SG.

3 Nov 2020

High Throughput Identification and Quantification of Breast Cancer With NMR-Based Metabolomics

Breast cancer is the leading cause of cancer-related death among the female population globally, despite the ever-growing technology of early detection.

From Bruker BioSpin Group 30 Oct 2020

Inflammasome may play a key role in triggering immune response to cancer

The inflammasome — a protein signaling network that is activated to rid the body of virus or bacteria-infected cells — may play an important role in triggering an immune response to cancer and causing an existing class of drugs to work better against cancers.

27 Oct 2020

Researchers recommend breast cancer screening for Black women aged 40 or below

Though Black women get breast cancer at a 3% lower incidence rate than white women, they are 42% more likely to die of breast cancer than white women.

27 Oct 2020

ACGT awards $500,000 grant to advance strategies for treating solid tumors

With a $500,000 Research Grant from Alliance for Cancer Gene Therapy, Sidi Chen, PhD, assistant professor in the Department of Genetics and Systems Biology Institute at Yale School of Medicine and member of Yale Cancer Center, will advance a versatile and highly scalable strategy he's been developing and calling MAEGI -- Multiplexed Activation of Endogenous Genes as an Immunotherapy.

6 Oct 2020

Researchers receive NCI grant to study role of collagens in breast cancer

An MUSC Hollings Cancer Center researcher received a $3 million grant from the National Cancer Institute to study how patterns of collagens can serve as biomarkers of breast cancer risk and potentially reveal clues to what might be driving health disparities.

1 Oct 2020

Researchers develop 'Trojan horse' approach to destroy cancer cells

Cancer cells are killed in lab experiments and tumour growth reduced in mice, using a new approach that turns a nanoparticle into a 'Trojan horse' that causes cancer cells to self-destruct, a research team at the Nanyang Technological University, Singapore (NTU Singapore) has found.

23 Sep 2020

Honeybee venom induces cancer cell death in aggressive breast cancer

The new study, published in the journal Nature Precision Oncology, highlights how bees can help combat breast cancer. The research team found that when the venom’s main component, when mixed with existing chemotherapy drugs, reduced tumor growth in laboratory mice.

2 Sep 2020

Developing more precise, targeted therapy for a highly aggressive breast cancer

Taking advantage of a cancer cell's altered metabolism that drives its runaway growth, Princess Margaret researchers are zeroing in on these molecular changes to help them develop more precise drug targets for one of the most deadly breast cancers.

21 Aug 2020

Key molecule can be used to assess prognosis of triple negative breast cancer

Hokkaido University scientists have shown that Interleukin-34 is a prognostic marker and drug target for Triple Negative Breast Cancer.

21 Aug 2020

New type of immunotherapy extends survival of mice with triple negative breast tumors

Immunotherapies for cancer - treatments that prime the immune system to attack tumors - are valuable weapons in the anti-cancer arsenal. But some cancers are more difficult to target with this strategy than others.

17 Aug 2020

HDAC6 inhibitors increase efficacy of immunotherapy in triple-negative breast cancer

Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published in the top-tier journal Cancer Research by investigators at the George Washington University (GW) Cancer Center.

6 Aug 2020

Eikonoklastes Therapeutics announces closing of oversubscribed seed financing

Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies for triple-negative breast cancer (TNBC) and several other diseases with unmet clinical need, today announced closing of an oversubscribed seed financing.

23 Jul 2020

Study finds viable drug target for triple negative breast cancer

One member of a larger family of oxygen sensing enzymes could offer a viable target for triple negative breast cancer (TNBC), UTSW researchers report in a new study.

23 Jul 2020

Researchers develop new nano drug that kills triple-negative breast cancer cells

Researchers at the University of Arkansas have developed a new nano drug candidate that kills triple negative breast cancer cells.

20 Jul 2020

Upcoming phase II study to discover personalized therapy for patients at high risk for breast cancer relapse

Indiana University School of Medicine researchers Milan Radovich, PhD, and Bryan Schneider, MD, have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women's blood who have undergone chemotherapy prior to surgery for the treatment of stage 1, 2 or 3 triple negative breast cancer are critical indicators for the prediction of disease recurrence and disease-free survival.

10 Jul 2020

Immunicom and Sheba Medical Center initiate clinical trial to evaluate novel cancer treatment

Sheba Medical Center at Tel HaShomer and Immunicom, Inc. are initiating a ground-breaking clinical trial to evaluate the clinical effectiveness of the Immunicom LW-02 plasma filtration device as a monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.

9 Jul 2020

Research shows IQGAP1 as a common target in variants of triple negative breast cancer

The cover for issue 26 of Oncotarget features Figure 6, "Mislocalization of IQGAP1-BRCA1 in human TNBC tumors phenocopies the dominant mutants and the TNBC cells," by Osman, et al. and reported that IQGAP1 is a signaling scaffold implicated in TNBC, but its mechanism is unknown.

30 Jun 2020